Materiality
72
Sentiment +73
Source
External coverage
Decided
2026-05-07
The payload explicitly ties Aclaris Therapeutics to a new 12-month high following an earnings beat, and the impact hints identify ACRS as the primary issuer target.
ACRS
Aclaris TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Curated Events
1
Active
Recent Headlines
0
New
Recent news sentiment
+0.1
30-day score
Company
-
30-day
Macro
-
30-day
Pulse
-
30-day
Curated events
Sentiment decomposition
+0.1
30-day score
Company-55%
Macro-30%
Pulse-15%
The 30-day sentiment score is a decayed blend of Company, Macro, and Pulse components.
Recent headlines
No supplemental ticker headlines stored yet
We are still collecting relevant articles for ACRS. Curated events highlight the most material developments impacting this ticker right now.
As of 2026-06-07 • Updated scheduledSource: News desk